Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

ÏàÔ¼µÂ¹ú·å»á| ÃÀ¸ß÷¾«×¼¾Û½¹´ÓÒ©Îï·¢Ã÷¹âÁÙ´²Ç°Ñо¿Ð§ÀÍ

2022-09-23
|
»á¼ûÁ¿£º

ÃÀ¸ß÷¾«×¼¾Û½¹´ÓÒ©Îï·¢Ã÷¹âÁÙ´²Ç°Ñо¿Ð§ÀÍ.jpg

¾«×¼Ò©Îï·¢Ã÷ & ¹âÁÙ´²Ç°Ñо¿·å»á £¨Precision in Drug Discovery & Preclinical  Summit£©½«ÓÚ2022Äê9ÔÂ27 - 28ÈÕÔÚµÂÍõ·¨À¼¿Ë¸£¾ÙÐС£¡£¡£¡£¡£¡£Precision in Drug Discovery & Preclinical Ô˶¯ÊǵÂÍõ·¨À¼¿Ë¸£×î´óµÄÉúÎïÖÆÒ©ÍøÂç £¬£¬£¬£¬£¬ÒÔʵÏÖÒ©Îï·¢Ã÷ºÍ¿ÆÑ§Õ½ÂÔµÄÆæÒìÏàÖúƽ̨¡£¡£¡£¡£¡£¡£±¾´Î·å»á½«Õ¹Ê¾ÖÆÒ©-ÉúÎï¼¼ÊõºÍѧÊõÁìÓòÏòµ¼ÕßµÄ×îÐÂÑо¿Ï£ÍûºÍÇ÷ÊÆ £¬£¬£¬£¬£¬°üÀ¨ÐÂÐÍ»¯ºÏÎï¡¢Ò©ÎïÉè¼Æ¡¢ºÏ³ÉÒªÁìºÍм¼Êõ £¬£¬£¬£¬£¬´Ó¶øÍƶ¯ÉúÎïÒ½Ò©Éú³¤¡£¡£¡£¡£¡£¡£ÃÀ¸ß÷ŷÖÞÍŶӽ«È«³Ì³öϯ´Ë´Î´ó»á £¬£¬£¬£¬£¬»¶Ó­µ½Õ¹Î»ºÅ3ÓëÎÒÃÇÏÖ³¡Ç¢Ì¸£¡

ʱ¼ä | 2022 9.27-9.28

ËùÔÚ | Frankfurt, Germany

չλ | 3

¹ØÓÚÃÀ¸ß÷

ÃÀ¸ß÷ÊÇÒ»¼ÒרҵµÄÉúÎïÒ½Ò©ÁÙ´²Ç°×ÛºÏÑз¢Ð§ÀÍCRO £¬£¬£¬£¬£¬ÎªÈ«ÇòµÄÒ½Ò©ÆóÒµºÍ¿ÆÑлú¹¹Ìṩȫ·½Î»µÄÇкϺ£ÄÚ¼°¹ú¼ÊÉ걨±ê×¼µÄһվʽÐÂÒ©Ñз¢Ð§ÀÍ¡£¡£¡£¡£¡£¡£ÎÒÃǹØ×¢È«ÇòÒ½Ò©ÐÐÒµÁ¢ÒìÉú³¤µÄÐèÇó £¬£¬£¬£¬£¬×¤×ãÓÚÁ¢ÒìÒ©ÎïÑз¢µÄÒªº¦»·½Ú £¬£¬£¬£¬£¬ÒÀ¸½Ð§Àͺ£ÄÚÍâÉúÎïÒ½Ò©ÐÐÒµËù»ýÀÛµÄÂÄÀú £¬£¬£¬£¬£¬¹¹½¨º­¸ÇÒ©Îï·¢Ã÷¡¢Ò©Ñ§Ñо¿ÒÔ¼°ÁÙ´²Ç°Ñо¿Òªº¦¼¼ÊõµÄ×ÛºÏÐÔ¼¼Êõƽ̨ £¬£¬£¬£¬£¬ÎªÈ«ÇòÉúÎïÒ½Ò©ÐÐÒµÌṩȫ·½Î»ÐÂÒ©ÁÙ´²Ç°Ñз¢Ð§ÀÍ¡£¡£¡£¡£¡£¡£ÖÁ2022ÄêÄêÖÐ £¬£¬£¬£¬£¬ÃÀ¸ß÷ÒÑΪȫÇòÁè¼Ý1710¼Ò¿Í»§ÌṩÐÂÒ©Ñз¢Ð§ÀÍ £¬£¬£¬£¬£¬¼ÓÈëÑз¢Íê³ÉµÄÐÂÒ©ÏîÄ¿ÓÐ268¼þIND»ñÅúÁÙ´² £¬£¬£¬£¬£¬Ó뺣ÄÚÍâÓÅÖʿͻ§ÅäºÏÉú³¤¡£¡£¡£¡£¡£¡£ÃÀ¸ß÷½«¼ÌÐø×¤×ãÈ«ÇòÊÓÒ° £¬£¬£¬£¬£¬¾ÛÁ¦ÖйúÁ¢Òì £¬£¬£¬£¬£¬ÎªÈËÀ࿵½¡Ð¢Ë³ÊµÁ¦£¡

ÃÀ¸ß÷Á¢ÒìÒ©ÎïÑз¢Ð§ÀÍ

PROTAC¼¼Êõƽ̨

ÃÀ¸ß÷ PROTAC Ò©Îï·¢Ã÷¼¼Êõƽ̨»ã×ÜÁËÄ¿½ñÊ¢ÐеÄÈÈÃŵİбêÂѰ×ÅäÌå £»£»£»½¨ÉèÁËÆÕ±éµÄÈÈÃŰÐÏòÂѰ׸߶ÈÇ׺ÍÁ¦Ð¡·Ö×Ó¼°Ð¡·Ö×ÓÆ¬¶Ï»¯ºÏÎï¿â (TPSM) £¬£¬£¬£¬£¬ÆÕ±éµÄ E3 ÅþÁ¬Ã¸ £¬£¬£¬£¬£¬¸ß¶ÈÇ׺ÍÁ¦µÄС·Ö×Ó¼°Ð¡·Ö×ÓÆ¬¶Ï (E3SM) £»£»£»½¨ÉèÁË Linkerϵͳ,°üÀ¨ÍøÂç´ó×Ú¾ßÓÐÆÕ±é¶àÑùÐÔµÄË«¹ÙÄÜÍÅÅþÁ¬Ìå (BF-Linker)¡£¡£¡£¡£¡£¡£ÕâЩ»ýÀ۵ϝºÏÎï¿â¿ÉÒÔ×ÊÖú¿ìËÙ¸ßЧµÄºÏ³É´ó×ڸ߻îÐÔ PROTAC Ë«ÌØÒìÐÔС·Ö×Ó £¬£¬£¬£¬£¬¼«´óµØÌá¸ß½ÓÄÉ PROTAC ¼¼Êõ¾ÙÐеÄÒ©ÎïÑз¢Àú³Ì¡£¡£¡£¡£¡£¡£³ýÁË¿ìËٺϳÉÖ®Íâ £¬£¬£¬£¬£¬ÎÒÃÇͬʱ½¨ÉèºÍÍêÉÆµÄPROTAC ÉúÎïɸѡÓë²âÊÔÆ½Ì¨ £¬£¬£¬£¬£¬ºóÐøÉú³¤¹âÁÙ´²Ç°ËùÓн׶Ρ£¡£¡£¡£¡£¡£

ADCÁÙ´²Ç°Ñз¢Ð§ÀÍÆ½Ì¨

ÃÀ¸ß÷ÔÚ ADC µÄÁÙ´²Ç°Ò»Ì廯Ñо¿¼Æ»®Öƶ©ÖÐÓë¿Í»§ÉîÈë½»Á÷ £¬£¬£¬£¬£¬½«Ã¿Ò»¸ö°¸ÀýµÄÌØµãÓë¶àÄêʵսÂÄÀúºÍ¼¼Êõ»ýÀÛÏàÁ¬Ïµ £¬£¬£¬£¬£¬ÉóÉ÷µØ½«ÓÅÖÊʵÑ鼯»®ÓëЧ¹ûÌá½»µ½¿Í»§ÊÖÉÏ¡£¡£¡£¡£¡£¡£ÃÀ¸ß÷¿ÉÒÔΪ¿Í»§Ìṩ ADC Payloads ºÏ³É¡¢ADC ҩЧѧÆÀ¼Û¡¢ADC Ò©´ú¶¯Á¦Ñ§ÆÀ¼ÛºÍ ADC Çå¾²ÐÔÆÀ¼ÛµÈЧÀÍ¡£¡£¡£¡£¡£¡£ÃÀ¸ß÷ÔÚ ADC Ò©ÎïÁÙ´²Ç°Ò©Ð§Ñ§¡¢Ò©ÎﶯÁ¦Ñ§¼°Çå¾²ÐÔÆÀ¼ÛÑо¿ÁìÓòÒÑ»ýÀÛÁËÉîÖ¿µÄÀíÂÛ»ù´¡ºÍ¸»ºñµÄʵ¼ùÂÄÀú¡£¡£¡£¡£¡£¡£×èÖ¹ÏÖÔÚ £¬£¬£¬£¬£¬ÃÀ¸ß÷ÒÑÍê³É 8 Ì×ÕûÌåÁÙ´²Ç°Ñо¿ÏîÄ¿ £¬£¬£¬£¬£¬ÔÚÖйú NMPA ºÍÃÀ¹ú FDA »ñÅúIND £¬£¬£¬£¬£¬²¢Óжà¸ö ADC ÏîÄ¿ÔÚÑС£¡£¡£¡£¡£¡£

mRNAÒßÃçÉúÎïÆÊÎö¼¼Êõƽ̨

»ùÓÚ mRNA ÒßÃçµÄ×÷ÓûúÖÆºÍÌØµã £¬£¬£¬£¬£¬ÃÀ¸ß÷ÉúÎï¼¼ÊõÒ©ÎïÆÊÎö²¿·ÖΪ֧³Ö mRNA ÒßÃçµÄÇå¾²ÐÔºÍÓÐÓÃÐÔÆÀ¼Û £¬£¬£¬£¬£¬½¨ÉèÁ˺­¸Ç´úл¼°ÉúÎïÂþÑÜ £¬£¬£¬£¬£¬µ½×Ü¿¹Ìå¡¢Òªº¦ÐòÁнṹÓò¿¹ÌåºÍ¿¹²¡¶¾ÖкͿ¹ÌåЧ¼Û £¬£¬£¬£¬£¬ÒÔ¼°Ï¸°ûÃâÒßÓ¦´ð·´Ó¦Ð§Á¦µÄϵÁÐÆÀ¼Û¼¼Êõƽ̨¡£¡£¡£¡£¡£¡£ÃÀ¸ß÷ºã¾ÃΪÖÖÖÖÐÂÐÍÉúÎï¼¼ÊõÒ©¼°ÒßÃçµÄÇå¾²ÐÔºÍÓÐÓÃÐÔÆÀ¼ÛÌṩȫ·½Î»Ö§³Ö £¬£¬£¬£¬£¬ÖÂÁ¦ÓÚ LNP-mRNA ÀàÒ©ÎïºÍÒßÃçµÄÓÐÓÃÐÔ¼°Çå¾²ÐÔÆÀ¼ÛÆÊÎöÊÂÇé £¬£¬£¬£¬£¬»ýÀÛÁ˸»ºñµÄÂÄÀú £¬£¬£¬£¬£¬½¨É轡ȫÁËÐÂÐÍ mRNA ÒßÃçµÄÏà¹ØÉúÎïÆÊÎö¼¼Êõƽ̨¡£¡£¡£¡£¡£¡£

AIÒ©ÎïÑз¢Á¢Òì

×÷Ϊ¿Æ´´°åCROµÚÒ»¹É £¬£¬£¬£¬£¬ÃÀ¸ß÷ÊôÓÚÐÐÒµÖнÏÔç¹Ø×¢µ½AI¼¼ÊõµÄÆóÒµ¡£¡£¡£¡£¡£¡£ÏÖÔÚ £¬£¬£¬£¬£¬ÃÀ¸ß÷ʹÓÃÉî¶ÈÉñ¾­ÍøÂç»úеѧϰ¼¼Êõ £¬£¬£¬£¬£¬¹¹½¨ÁËBTKÒÖÖÆ¼ÁÒ©ÎïÉè¼ÆÄ£×Ó £¬£¬£¬£¬£¬²¢ÖÂÁ¦ÓÚ½¨Éè BTK ÒÖÖÆ¼ÁÒ©Îï·Ö×ÓÉè¼ÆÒÔ¼°É¸Ñ¡Æ½Ì¨ £¬£¬£¬£¬£¬·¢Á¦¡°CRO+AI¡± £¬£¬£¬£¬£¬¼ÓËÙÐÂÒ©Ñз¢Àú³Ì¡£¡£¡£¡£¡£¡£

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿